Core Insights - electroCore, Inc. will report its financial results for Q3 2025 on November 5, 2025, after market close [1] - A webinar will be held at 4:30 PM EST on the same day to discuss the results and answer investor questions [1] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [2] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device, and Quell neurostimulator, both aimed at treating chronic pain syndromes [2] - Additionally, electroCore offers Truvaga and TAC-STIM products for general wellness and human performance enhancement [2]

Core Insights - electroCore, Inc. announced that its Truvaga™ Plus handheld vagus nerve stimulation device was named the "Best Relaxation Gadget" in Esquire's 2025 Sleep Awards, highlighting its effectiveness in promoting relaxation and restorative sleep [1][2] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies. Its leading products include gammaCore for chronic pain and Truvaga for general wellness [3][5] Product Details - Truvaga Plus is designed to activate the vagus nerve quickly and gently, promoting a balanced nervous system for improved calmness, clarity, and sleep. It is intended for general health and wellness and is not a medical device [5][6] - The device offers a drug-free alternative for relaxation and sleep, with sessions lasting just two minutes, making it convenient for daily use [8] Recognition and Validation - The recognition from Esquire serves as validation for Truvaga Plus, reinforcing consumer confidence in its effectiveness as a proven, non-drug solution for sleep and relaxation challenges [2][3]

Core Insights - electroCore, Inc. has appointed James C. Theofilos to its Board of Directors effective August 1, 2025, highlighting the company's commitment to enhancing its leadership team [1][2] - Mr. Theofilos brings nearly two decades of experience in finance and strategic growth, particularly in the healthcare and life sciences sectors, which is expected to benefit electroCore's operational discipline and innovation [2] - electroCore focuses on improving health and quality of life through non-invasive bioelectronic technologies, with its leading products including gammaCore and Quell neurostimulator for chronic pain treatment [3] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company dedicated to innovative non-invasive solutions for health improvement [3] - The company's primary products, gammaCore and Quell, utilize non-invasive vagus nerve stimulation technology to address chronic pain syndromes [3] - Additionally, electroCore markets Truvaga products, which are designed for personal use to enhance general wellness and human performance [3]

Company Overview - electroCore is a commercial-stage bioelectronic medicine and wellness company focused on multiple indications[6] - The company has FDA clearance for the prevention and treatment of primary headache in adults and adolescents[13] - The company has FDA authorization for symptoms of Fibromyalgia[13] Financial Performance and Projections - The company's revenue has a 5-year CAGR of 58%[7] - Revenue increased from $5.5 million in 2021 to $25.2 million in 2024[12] - Revenue is projected to reach $30 million in 2025[12] - Gross margins are approximately 85%[13] Market Opportunity - The total addressable market (TAM) for VA channel is $2.9 billion[15] - The total addressable market (TAM) for US commercial channel is $101 million[15] - The total addressable market (TAM) for Health & Wellness channel is $33 billion[15] - The total addressable market (TAM) for TAC-STIM is $9.7 billion[15] - $20 billion is spent annually out-of-pocket for chronic pain treatments[14]